📊 COGT Key Takeaways
Is Cogent Biosciences, Inc. (COGT) a Good Investment?
Cogent Biosciences is in severe financial distress with catastrophic operating losses (-$333.4M) and negative free cash flow (-$266.0M), indicating the company is burning cash rapidly despite having $312.0M in reserves. Revenue has collapsed 65% YoY to just $7.9M, demonstrating fundamental business deterioration that vastly exceeds cash runway sustainability. The combination of massive operating losses, negative margins exceeding -4000%, and severely negative return metrics indicates a company in existential crisis with minimal near-term path to profitability.
Cogent Biosciences shows weak current fundamentals, with very limited revenue, extreme negative operating and net margins, and large ongoing cash burn that indicates the business is still heavily dependent on external funding or existing balance-sheet reserves. The balance sheet is not distressed today because liquidity is strong and debt is moderate relative to equity, but growth quality is poor and the path to sustainable profitability remains highly uncertain.
Why Buy Cogent Biosciences, Inc. Stock? COGT Key Strengths
- Adequate liquidity position with $312.0M in cash and 14.23x current ratio providing near-term operational runway
- Manageable debt-to-equity ratio of 0.35x suggesting moderate leverage relative to equity base
- Positive stockholders equity of $636.4M provides balance sheet cushion against further losses
- Strong liquidity with $312.01M in cash and 14.23x current and quick ratios
- Equity base remains solid at $636.37M, limiting near-term balance sheet stress
- Debt load is manageable relative to equity at 0.35x
COGT Stock Risks: Cogent Biosciences, Inc. Investment Risks
- Catastrophic revenue decline of 65% YoY indicates severe business contraction and loss of market traction
- Massive operating losses of -$333.4M with negative FCF of -$266.0M consuming cash reserves at unsustainable rate
- Negative operating margin of -4235% and net margin of -4179% indicate business model is fundamentally broken with no path to profitability visible
- Operating cash burn of -$264.4M annually means current $312.0M cash reserves provide only ~14 months of runway at current burn rate
- Diluted EPS of -$2.16 and worsening 11.3% YoY suggests continued shareholder value destruction
- Revenue fell 65.0% YoY, indicating weak and potentially nonrecurring commercial traction
- Operating loss of $333.36M and free cash flow of -$266.00M reflect severe ongoing cash burn
- Net margin of -4179.1% shows the business is far from self-sustaining profitability
Key Metrics to Watch
- Quarterly revenue trend and stabilization of product sales pipeline
- Operating cash burn rate and cash runway remaining before liquidity crisis
- Operating expenses reduction initiatives and pathway to operating profitability
- Clinical trial progress and regulatory approvals for pipeline assets
- Cash position depletion trajectory relative to quarterly burn rates
- Quarterly operating cash burn relative to cash balance
- Revenue durability and improvement in operating loss trajectory
Cogent Biosciences, Inc. (COGT) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 14.23x current ratio provides a solid financial cushion.
COGT Profit Margin, ROE & Profitability Analysis
COGT vs Healthcare Sector: How Cogent Biosciences, Inc. Compares
How Cogent Biosciences, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Cogent Biosciences, Inc. Stock Overvalued? COGT Valuation Analysis 2026
Based on fundamental analysis, Cogent Biosciences, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Cogent Biosciences, Inc. Balance Sheet: COGT Debt, Cash & Liquidity
COGT Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Cogent Biosciences, Inc.'s revenue has declined by 19% over the 5-year period, indicating business contraction. The most recent EPS of $-1.94 indicates the company is currently unprofitable.
COGT Revenue Growth, EPS Growth & YoY Performance
COGT Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2021 | $312.0K | -$6.1M | N/A |
| Q2 2021 | $528.0K | -$6.1M | N/A |
| Q1 2021 | $7.0M | -$6.1M | N/A |
| Q3 2020 | $312.0K | -$6.1M | N/A |
| Q2 2020 | $528.0K | -$6.1M | N/A |
| Q1 2020 | $3.1M | -$6.1M | N/A |
| Q3 2019 | $1.0M | -$6.7M | N/A |
| Q2 2019 | $1.7M | -$6.7M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Cogent Biosciences, Inc. Dividends, Buybacks & Capital Allocation
COGT SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Cogent Biosciences, Inc. (CIK: 0001622229)
📋 Recent SEC Filings
❓ Frequently Asked Questions about COGT
What is the AI rating for COGT?
Cogent Biosciences, Inc. (COGT) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (SELL) with 88% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are COGT's key strengths?
Claude: Adequate liquidity position with $312.0M in cash and 14.23x current ratio providing near-term operational runway. Manageable debt-to-equity ratio of 0.35x suggesting moderate leverage relative to equity base. ChatGPT: Strong liquidity with $312.01M in cash and 14.23x current and quick ratios. Equity base remains solid at $636.37M, limiting near-term balance sheet stress.
What are the risks of investing in COGT?
Claude: Catastrophic revenue decline of 65% YoY indicates severe business contraction and loss of market traction. Massive operating losses of -$333.4M with negative FCF of -$266.0M consuming cash reserves at unsustainable rate. ChatGPT: Revenue fell 65.0% YoY, indicating weak and potentially nonrecurring commercial traction. Operating loss of $333.36M and free cash flow of -$266.00M reflect severe ongoing cash burn.
What is COGT's revenue and growth?
Cogent Biosciences, Inc. reported revenue of $7.9M.
Does COGT pay dividends?
Cogent Biosciences, Inc. does not currently pay dividends.
Where can I find COGT SEC filings?
Official SEC filings for Cogent Biosciences, Inc. (CIK: 0001622229) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is COGT's EPS?
Cogent Biosciences, Inc. has a diluted EPS of $-2.16.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is COGT a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Cogent Biosciences, Inc. has a SELL rating with 88% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is COGT stock overvalued or undervalued?
Valuation metrics for COGT: ROE of -51.7% (sector avg: 15%), net margin of -4,179.1% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy COGT stock in 2026?
Our dual AI analysis gives Cogent Biosciences, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is COGT's free cash flow?
Cogent Biosciences, Inc.'s operating cash flow is $-264.4M, with capital expenditures of $1.6M. FCF margin is -3,379.5%.
How does COGT compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -4,179.1% (avg: 12%), ROE -51.7% (avg: 15%), current ratio 14.23 (avg: 2).